Back to today’s briefing

Story perspectives

Diabetes Drug Pioglitazone May Prevent Prostate Cancer Recurrence

5/22/2025

33 7

Summary

Story summary

A groundbreaking study in Molecular Cancer suggests that pioglitazone, a diabetes medication, could significantly lower the risk of prostate cancer recurrence in diabetic men. Over nearly ten years, researchers tracked 69 patients, discovering that those on pioglitazone experienced no cancer relapses. Further trials are essential to assess its potential for non-diabetic patients.

1 of 1

Story summary

A groundbreaking study in Molecular Cancer suggests that pioglitazone, a diabetes medication, could significantly lower the risk of prostate cancer recurrence in diabetic men. Over nearly ten years, researchers tracked 69 patients, discovering that those on pioglitazone experienced no cancer relapses. Further trials are essential to assess its potential for non-diabetic patients.